Drug Profile
ZP 4982
Alternative Names: ZP4982Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Developer Boehringer Ingelheim; Zealand Pharma
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Amylin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Diabetes mellitus in Denmark (SC) (Zealand Pharma pipeline, September 2023)
- 04 Sep 2023 Discontinued - Preclinical for Diabetes mellitus in Germany (SC) (Zealand Pharma pipeline, September 2023)
- 04 Sep 2023 Discontinued - Preclinical for Obesity in Denmark (SC) (Zealand Pharma pipeline, September 2023)